Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 StudyRathana Kim, Emmanuelle Clappier, Yosr Hicheri et al.|Journal of Clinical Oncology|2024Cited by 39
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 <sup>+</sup> Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic LeukemiaJean‐Baptiste Robin, Thibaut Leguay, Marc Delord et al.|Journal of Clinical Oncology|2024Cited by 33
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemiaYves Chalandon, Hervé Dombret, Philippe Rousselot et al.|Blood|2024Cited by 28
Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantationLudovic Lhermitte, Rathana Kim, Nicolas Boissel et al.|Leukemia|2020Cited by 27
Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 TrialRathana Kim, Emmanuelle Clappier, Philippe Rousselot et al.|Blood|2021Cited by 9